OKYO PHARMA LTD SP.ADR/65 Net Assets
OKYO PHARMA LTD SP.ADR/65 net assets. Based on the latest financial reports, OKYO PHARMA LTD SP.ADR/65 (OK10) has net assets worth €-3.42 Million EUR (≈ $-3.99 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€4.64 Million ≈ $5.43 Million USD) and total liabilities (€8.06 Million ≈ $9.42 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore OK10 shareholders equity momentum to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €-3.42 Million |
| % of Total Assets | -73.54% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
Net Assets of OKYO PHARMA LTD SP.ADR/65 (2022–2025)
Net assets of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025. This chart illustrates how OKYO PHARMA LTD SP.ADR/65's net assets have evolved over time, based on quarterly financial data. See OK10 net asset quality score to measure how much of total assets are equity-financed.
Annual Net Assets for OKYO PHARMA LTD SP.ADR/65 (2022–2025)
The table below shows the annual net assets of OKYO PHARMA LTD SP.ADR/65 from 2022 to 2025. For live market cap and overall valuation, see OKYO PHARMA LTD SP.ADR/65 (OK10) total market value.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | €-5.55 Million ≈ $-6.49 Million |
+5.61% |
| 2024-03-31 | €-5.88 Million ≈ $-6.87 Million |
-186.36% |
| 2023-03-31 | €-2.05 Million ≈ $-2.40 Million |
-169.66% |
| 2022-03-31 | €2.95 Million ≈ $3.45 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to OKYO PHARMA LTD SP.ADR/65's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3059893800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
OKYO PHARMA LTD SP.ADR/65 Net Assets Breakdown (March 2025)
OKYO PHARMA LTD SP.ADR/65 net assets breakdown by equity component as of March 2025.
| Component | Amount | Percentage |
|---|---|---|
| Other Components | €137.48 Million | % |
| Total Equity | €-5.55 Million | 100.00% |
OKYO PHARMA LTD SP.ADR/65 Competitors by Market Cap
The table below lists competitors of OKYO PHARMA LTD SP.ADR/65 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
UPA Corporation Bhd
KLSE:7757
|
$38.38 Million |
|
Xos Inc
NASDAQ:XOS
|
$38.39 Million |
|
Isofol Medical AB
ST:ISOFOL
|
$38.42 Million |
|
Superlon Holdings Bhd
KLSE:7235
|
$38.42 Million |
|
Abnova Taiwan Corp
TW:4133
|
$38.35 Million |
|
Highlight Communications AG
XETRA:HLG
|
$38.35 Million |
|
eXoZymes, Inc.
NASDAQ:EXOZ
|
$38.33 Million |
|
Korea Electronic Certification Authority Inc
KQ:041460
|
$38.32 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in OKYO PHARMA LTD SP.ADR/65's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from -5,879,582 to -5,549,555, a change of 330,027.
- Net loss of 4,706,292 reduced equity.
- New share issuances of 1,705,742 increased equity.
- Other factors increased equity by 3,330,577.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-4.71 Million | -84.8% |
| Share Issuances | €1.71 Million | +30.74% |
| Other Changes | €3.33 Million | +60.02% |
| Total Change | €- | % |
Book Value vs Market Value Analysis
This analysis compares OKYO PHARMA LTD SP.ADR/65's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-03-31 | €0.14 | €1.36 | x |
| 2023-03-31 | €-0.04 | €1.36 | x |
| 2024-03-31 | €-0.18 | €1.36 | x |
| 2025-03-31 | €-0.15 | €1.36 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently OKYO PHARMA LTD SP.ADR/65 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-46.07%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -184.27% | 0.00% | 0.00x | 1.46x | €-5.73 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | €-13.07 Million |
| 2024 | 0.00% | 0.00% | 0.00x | 0.00x | €-16.24 Million |
| 2025 | 0.00% | 0.00% | 0.00x | 0.00x | €-4.15 Million |
Industry Comparison
This section compares OKYO PHARMA LTD SP.ADR/65's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $165,369,067
- Average return on equity (ROE) among peers: -55.63%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| OKYO PHARMA LTD SP.ADR/65 (OK10) | €-3.42 Million | -184.27% | N/A | $38.38 Million |
| TME PHARM.CONF.IPO EO 1- (0N6A) | $4.50 Million | -321.01% | 1.17x | $10.44 Million |
| PROQR THERAPEUTICS EO-04 (0PQ) | $88.56 Million | -31.35% | 0.90x | $142.34 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $41.28 Million | -56.73% | 0.18x | $141.34 Million |
| Theravance Biopharma Inc (0TB) | $-51.59 Million | 0.00% | 0.00x | $828.57 Million |
| I-MAB SPONS.ADS/1 -0001 (0VY) | $715.33 Million | -51.14% | 0.23x | $141.97 Million |
| PreveCeutical Medical Inc (18H) | $-4.64 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $63.37 Million | -33.73% | 0.67x | $41.67 Billion |
| GH RESEARCH PLC DL-025 (1KA) | $277.18 Million | -3.32% | 0.01x | $1.22 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $518.36 Million | -39.43% | 0.23x | $714.18 Million |
| BIOCURE TECHNOLOGY INC. (1WH) | $1.34 Million | -19.58% | 0.49x | $960.84K |
About OKYO PHARMA LTD SP.ADR/65
OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptid… Read more